Lahtela-Kakkonen M - Search Results

1

PE and PET oligomers' interplay with membrane bilayers.

Järvenpää J, Perkkiö M, Laitinen R, Lahtela-Kakkonen M. Järvenpää J, et al. Among authors: lahtela kakkonen m. Sci Rep. 2022 Feb 9;12(1):2234. doi: 10.1038/s41598-022-06217-4. Sci Rep. 2022. PMID: 35140293 Free PMC article.

2

Natural polyphenols as sirtuin 6 modulators.

Rahnasto-Rilla M, Tyni J, Huovinen M, Jarho E, Kulikowicz T, Ravichandran S, A Bohr V, Ferrucci L, Lahtela-Kakkonen M, Moaddel R. Rahnasto-Rilla M, et al. Sci Rep. 2018 Mar 7;8(1):4163. doi: 10.1038/s41598-018-22388-5. Sci Rep. 2018. PMID: 29515203 Free PMC article.

3

Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities.

Rahnasto-Rilla M, Järvenpää J, Huovinen M, Schroderus AM, Ihantola EL, Küblbeck J, Khadeer M, Moaddel R, Lahtela-Kakkonen M. Rahnasto-Rilla M, et al. Among authors: lahtela kakkonen m. Biomed Pharmacother. 2020 Nov;131:110701. doi: 10.1016/j.biopha.2020.110701. Epub 2020 Sep 6. Biomed Pharmacother. 2020. PMID: 32905943 Free article.

4

Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.

Järvenpää J, Rahnasto-Rilla M, Lahtela-Kakkonen M, Küblbeck J. Järvenpää J, et al. Among authors: lahtela kakkonen m. Biomed Pharmacother. 2022 Mar;147:112652. doi: 10.1016/j.biopha.2022.112652. Epub 2022 Jan 19. Biomed Pharmacother. 2022. PMID: 35065514 Free article.

5

A systems biology network analysis of nutri(epi)genomic changes in endothelial cells exposed to epicatechin metabolites.

Milenkovic D, Berghe WV, Morand C, Claude S, van de Sandt A, Gorressen S, Monfoulet LE, Chirumamilla CS, Declerck K, Szic KSV, Lahtela-Kakkonen M, Gerhauser C, Merx MW, Kelm M. Milenkovic D, et al. Sci Rep. 2018 Oct 19;8(1):15487. doi: 10.1038/s41598-018-33959-x. Sci Rep. 2018. PMID: 30341379 Free PMC article.

6

Micro-sized polyethylene particles affect cell viability and oxidative stress responses in human colorectal adenocarcinoma Caco-2 and HT-29 cells.

Herrala M, Huovinen M, Järvelä E, Hellman J, Tolonen P, Lahtela-Kakkonen M, Rysä J. Herrala M, et al. Among authors: lahtela kakkonen m. Sci Total Environ. 2023 Apr 1;867:161512. doi: 10.1016/j.scitotenv.2023.161512. Epub 2023 Jan 7. Sci Total Environ. 2023. PMID: 36626990 Free article.

7

Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.

Jyrkkärinne J, Windshügel B, Rönkkö T, Tervo AJ, Küblbeck J, Lahtela-Kakkonen M, Sippl W, Poso A, Honkakoski P. Jyrkkärinne J, et al. J Med Chem. 2008 Nov 27;51(22):7181-92. doi: 10.1021/jm800731b. J Med Chem. 2008. PMID: 18983136

8

N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.

Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, Bruijn T, Jääskeläinen S, Poso A, Salminen A, Leppänen J, Jarho E. Huhtiniemi T, et al. Bioorg Med Chem. 2010 Aug 1;18(15):5616-25. doi: 10.1016/j.bmc.2010.06.035. Epub 2010 Jun 17. Bioorg Med Chem. 2010. PMID: 20630764

9

Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.

Huhtiniemi T, Salo HS, Suuronen T, Poso A, Salminen A, Leppänen J, Jarho E, Lahtela-Kakkonen M. Huhtiniemi T, et al. J Med Chem. 2011 Oct 13;54(19):6456-68. doi: 10.1021/jm200590k. Epub 2011 Sep 7. J Med Chem. 2011. PMID: 21895016

10

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.

Martikainen LE, Rahnasto-Rilla M, Neshybova S, Lahtela-Kakkonen M, Raunio H, Juvonen RO. Martikainen LE, et al. Eur J Pharm Sci. 2012 Dec 18;47(5):996-1005. doi: 10.1016/j.ejps.2012.09.018. Epub 2012 Oct 13. Eur J Pharm Sci. 2012. PMID: 23069620

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page